Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

  • Medical Education & Research
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma
- Collapse

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • New clinical practice guidelines for treating multiple myeloma

    May 2019

    Mikhael J, et al., J Clin Oncol – A panel of experts convened by the American Society of Clinical Oncology and Cancer Care Ontario examined 124 published studies identified through a literature search on treating multiple myeloma to develop consensus, evidence-based recommendations for the treatment of patients who are transplant eligible and those who are ineligible and for patients with relapsed or refractory disease. 

    Read More

  • MRD-negative status prognostic for PFS and OS for patients with multiple myeloma

    March 2019
    Hahn TE, et al., Bio Blood Marrow Transplant – Researchers found that minimal residual disease (MRD)-negative status may be a valuable addition with other clinical factors in determining further therapy needs for patients with multiple myeloma (MM). It can be prognostic for progression-free survival (PFS) and overall survival (OS) for patients with MM.

    Read More

  • Delayed Auto-HCT Can Lead to Inferior Survival Rates in Patients with MM

    May 2018
    Kansagra A, et al. Biol Blood Marrow Transplant – Patients with multiple myeloma (MM) who undergo stem cell collection in preparation for an autologous HCT have lower outcomes if they delay transplant and are unable to receive their stem cells due to disease relapse.

    Read More

  • Allo-HCT Can Be an Effective Salvage Therapy for Multiple Myeloma

    January 2018
    Montefusco V, et al. Bone Marrow Transplant – In this study of 71 patients with multiple myeloma undergoing hematopoietic cell transplantation (HCT), 5-year overall survival (OS) was 60%, with better outcomes in patients ≤55 years and in those transplanted with chemosensitive disease.

    Read More

  • Auto-HCT Can Be Safe for Myeloma Patients with Renal Insufficiency

    November 2017
    Mahindra A, et al. Bone Marrow Transplant – In this study, researchers analyzed autologous hematopoietic cell transplantation (HCT) outcomes in 1,492 patients with multiple myeloma (MM) and renal insufficiency (RI).

    Read More

  • Cyclophosphamide Can Lower GVHD Rates in Patients with MM

    August 2017
    Ghosh N, et al. Biol Blood Marrow Transplant – Allogeneic hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide can be safely performed in patients with multiple myeloma (MM), resulting in low rates of both acute and chronic graft-versus-host disease and rates of non-relapse mortality.

    Read More

  • Study Finds Disparity in HCT Utilization for Hispanics with Multiple Myeloma

    June 2017
    Schriber JR, et al. Cancer – A study of 28,450 patients who underwent autologous HCT for multiple myeloma found that the rate of transplant utilization in the U.S. was significantly lower for Hispanic patients compared to non-Hispanic whites. The analysis also found that race/ethnicity did not affect post-transplant outcomes.

    Read More

  • Autologous HCT Plus RVD Therapy May Be Best for Patients with MM

    May 2017
    Attal M, et al. N Engl J Med – A randomized trial of 700 patients with multiple myeloma (MM) has found that median progression-free survival is significantly longer in patients who underwent autologous HCT after combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) than in patients who received RVD alone: 50 months vs. 36 months, respectively (p<0.001).

    Read More

  • No Benefit of Additional Treatment After Auto-HCT for Myeloma with Lenalidomide Maintenance

    December 2016
    Stadtmauer E, et al. ASH abstract oral presentation, December 2016 – The addition of consolidation therapy or a second autologous transplant is not superior to a single autologous transplant followed by lenalidomide maintenance in the upfront treatment of multiple myeloma, according to research presented at the Late-Breaking Abstracts session at ASH.

    Read More

  • Post-HCT Therapies May Improve Outcomes for Patients with High-Risk Myeloma

    November 2016
    Scott EC, et al. Biol Blood Marrow Transplant – Therapies using bortezomib and immunomodulatory agents after autologous hematopoietic cell transplantation (HCT) for patients with high-risk (HR) multiple myeloma appears to contribute to improved HCT outcomes, with 3-year overall survival (OS) of 81%.

    Read More

  • In Era of Novel Agents, Autologous Transplant Still Preferred Treatment for Multiple Myeloma

    August 2016
    Cavo M, et al. ASCO abstract oral presentation, June 2016 – Up-front autologous stem cell transplantation (ASCT) should remain the preferred treatment for younger patients who are newly diagnosed with multiple myeloma, according to results of a clinical trial reported at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

    Read More

  • Review: Allogeneic HCT to Treat High-Risk Multiple Myeloma

    January 2016
    Dhakal B, et al. Bone Marrow Transplant – In this review, the authors outline the use of allogeneic hematopoietic cell transplantation (HCT) to treat multiple myeloma (MM), noting that allogeneic HCT should be strongly considered only for high-risk MM patients as part of their initial course of therapy or in first chemotherapy-sensitive relapse within a clinical trial.

    Read More

  • Salvage Autologous Transplant Better than Non-Transplant Therapy in Relapsed Multiple Myeloma

    December 2015
    Cook G, et al. ASH abstract oral presentation, December 2015 - A second autologous hematopoietic cell transplant (HCT) in multiple myeloma (MM) patients relapsing after a prior autologous HCT leads to better overall survival than non-transplant therapy, according to research presented at the ASH Annual Meeting.

    Read More

  • Autologous Transplantation for Multiple Myeloma in the Era of New Drugs

    December 2015
    Attal M, et al. ASH abstract oral presentation, December 2015 - A multi-center randomized trial of 700 patients <65 years old with de novo multiple myeloma (MM) has shown that autologous hematopoietic cell transplantation (HCT) following treatment with lenalidomide, bortezomib and dexamethasone (RVD) is better than treatment with these drugs alone.

    Read More

  • Consensus Report: Salvage Therapy with HCT for Relapsed Multiple Myeloma

    October 2015
    Giralt S, et al. Biol Blood Marrow Transplant – This consensus report from four professional transplant organizations establishes recommendations on the role of high-dose therapy with autologous or allogeneic HCT in multiple myeloma patients relapsing after primary therapy.

    Read More

  • Novel Agents for Consolidation and Maintenance Therapy After Auto-HCT for Multiple Myeloma

    August 2015
    Mohty M, et al. Bone Marrow Transplant – Substantial improvements in the depth of response prior to transplant has been seen with the use of novel agents such as proteasome inhibitors and immunomodulatory drugs.

    Read More

  • Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma

    July 2015
    Graff TM, et al. Bone Marrow Transplant – Researchers comparing outcomes of 230 patients with myeloma or lymphoma who underwent autologous hematopoietic cell transplantation (HCT) on an inpatient vs. outpatient basis within a single transplant program have found comparable outcomes in the two cohorts.

    Read More

  • ASBMT Evidence-Based Review: The Role of HCT in Multiple Myeloma

    June 2015
    Shah N, et al. Biol Blood Marrow Transplant — This systematic evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) evaluated the role of hematopoietic cell transplantation (HCT) in the treatment of multiple myeloma.

    Read More

  • Favorable Overall Survival Results for Allogeneic HCT in Patients with Multiple Myeloma

    July 2014
    Donato ML, et al. Biol Blood Marrow Transplant — In this prospective study of 57 patients with multiple myeloma, 26 underwent allogeneic HCT for consolidation after a response to their first autologous transplant, and 30 patients received an allogeneic HCT as salvage therapy.

    Read More

  • Lenalidomide Maintenance after HCT for High-Risk Multiple Myeloma

    July 2014
    Alsina M, et al. Biol Blood Marrow Transplant — A multi-center study of 30 high-risk patients transplanted for multiple myeloma has demonstrated 18-month overall survival of 78% for patients who received post-transplant lenalidomide maintenance therapy.

    Read More

  • Significant Improvement in HCT Survival Over Time

    June 2013

    Hahn T, et al. J Clin Oncol - Survival for patients undergoing allogeneic hematopoietic cell transplantation (HCT) has significantly improved over time, according to a study of 38,060 patients with hematologic malignancies transplanted between 1994 and 2005 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • Graft-Versus-Tumor Effects in Advanced Malignancies

    March 2013

    Storb R, et al. J Clin Oncol - A study of a minimal-intensity pre-transplant conditioning regimen consisting of low-dose total body irradiation with or without fludarabine has shown that it can induce strong graft-versus-tumor (GVT) effects leading to lasting remissions in 45% to 75% of patients.

    Read More

  • Lenalidomide after Autologous HCT for Multiple Myeloma Improves Survival

    May 2012
    McCarthy PL, et al. N Eng J Med — Lenalidomide maintenance therapy following autologous hematopoietic cell transplantation (HCT) results in a significantly longer time to disease progression and significantly improved overall survival among patients with multiple myeloma.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma